Psoriasis är en av de vanligast förekommande hudsjukdomarna och mer än två procent har denna kroniska sjukdom i Sverige. Som allmänsjuksköterska är sannolikheten stor att vi kommer att stöta på patienter med sjukdomen. Syftet med denna studie var att öka kunskapen och fördjupa förståelsen för personer med denna sjukdom ur aspekterna livskvalitet, copingstrategier samt ta reda på om sjuksköterskan med några omvårdnadsåtgärder kan underlätta för patienter med psoriasis. Denna litteraturstudie visade tydligt att psoriasis påverkar livskvalitén. För att få fram den kunskapen använde man olika mätinstrument. Det framkom att det fysiska, psykiska och sociala livet påverkades samt ekonomin. När det gällde copingstrategier fann man att oavsett om man var frisk eller sjuk använde man samma strategier. Ingen forskning har bedrivits angående omvårdnadsåtgärder rörande psoriasis för allmänsjuksköterskan. Mer forskning behövs kring allmänsjuksköterskans vårdande roll. Denna studie har trots detta ett framtida värde då den ger värdefull information som vi kan använda oss av i omvårdnadsarbetet. / Psoriasis is one of the most common skin-diseases and more than two percent suffers from this chronic disease in Sweden. As a general nurse it is very likely that we will meet patients with this disease. We want to create a greater understanding and knowledge about how a nurse can support and make it easier for these patients. The aim of this study was to increase the knowledge and deepens the understanding of patients with psoriasis regarding aspects of quality of life, copingstrategies and nursinginterventions. This literature review clearly showed that psoriasis influenced quality of life. To get these results the researchers used different kinds of instruments. It showed that physical, psychological and social life where affected and also their financial state. When it came to copingstrategies the findings showed that no matter if you were healthy or sick you used the same kind of strategies. No research has been done about nursing interventions for the general nurse. We therefore need more research about the general nurses care-giving roll. This study has though a future value as it gives us information about what we can do for patients with psoriasis in our nursing care.

Introduction Grenz ray therapy ( has long been used as treatment for inflammatory skindiaseases R ecent h ealth technology assessment reports have concluded that because ofinsufficient evidence of its efficacy they do not promote further use of GRT for benigndisorders. Aim T o investigate the effect, estimate remission times and summarize the outcome of the GRTseries administered over a six year period for the treatment of inflammatory diseases at theUniversity Hospital Örebro Methods A total of 204 treatment serie s were included by review of patient files spanningfrom 201 5 to 2020. Symptom scores of one to fifteen were recorded at start and end oftreatment. Data on recurrence was collected over a follow up period of 12 months after theend of treatment. Results Al l diagnoses had reduced symptom severity score s post treatment, with psoriasis ofthe scalp showing a 71.4% reduction and genital lichen showing a symptom score reductionof 25.0% Non reponse was lowest for hand dermatitis, and highest for lichen and eczema ofthe body. In patients with an initial effect post t reatment, a majority did not experience arecurrence within 12 months. Conclusion Positive effects were of GRT was indicated especially for scalp psoriasis andhand dermatitis, a ltough effect size is undetermined. The least effect was indicated for genitallichen. Hand dermatitis had the lowest recurrence rate in the follow up period. Furtherresearch of the subject is needed to determine the utility o f the method

Psoriasis is a chronic inflammatory disease of the skin and joints associated with several comorbidities such as arthritis, diabetes mellitus and metabolic syndrome, including obesity, hypertension and dyslipidaemia, Crohn’s disease, uveitis and psychiatric and psychological diseases. Psoriasis has been described as an independent risk factor for cardiovascular diseases and thus patients with psoriasis should be monitored for the development of cardiovascular disease or metabolic syndrome. However, there is mounting evidence that psoriasis also affects the development of osteoporosis, an important metabolic disease with enormous clinical and socioeconomic impact. At present, there are still controversial opinions about the role of psoriasis in osteoporosis. A more in depth analysis of this phenomenon is of great importance for affected patients since, until now, bone metabolism is not routinely examined in psoriatic patients, which might have important long-term consequences for patients and the health system. In the present review, we summarize current knowledge on the impact of psoriatic inflammation on bone metabolism and osteoporosis.

Psoriasis is an immune mediated inflammatory disease which affects 2-3% of the world’s population. Over the last decade, psoriasis has been acknowledged as an independent risk factor for atherosclerosis. The precise mechanism or mechanisms of the heightened risk is widely speculated. Endothelial cells and macrophages are central players in the immunopathological development of both diseases. Interleukin-36 cytokines (IL-36) have been heavily implicated in psoriasis immunopathology. Significant upregulation of epidermal IL-36 is a recognised characteristic of psoriatic skin inflammation. IL-36 induces inflammatory responses in dendritic cells, fibroblasts and epithelial cells. While vascular alterations are a hallmark of psoriatic lesions and dermal endothelial cells are well known to play a critical role in dermal inflammation, the effects of IL-36 on endothelial cells have not been defined. We report that endothelial cells including dermal microvascular cells express a functionally active IL-36 receptor. Adhesion molecules VCAM-1 and ICAM-1 are upregulated following IL-36γ stimulation, and this is reversed in the presence of the endogenous IL-36 receptor antagonist. IL-36γ-stimulated endothelial cells secrete the proinflammatory chemokines IL-8, CCL2 and CCL20. Chemotaxis assays showed increased migration of T-cells following IL-36γ stimulation of endothelial cells. Both resident and infiltrating inflammatory myeloid cells contribute to the immunopathology of psoriasis by promoting the IL-23/IL-17 axis. We show that IL-36γ induces the production of psoriasis-associated cytokines from macrophages (IL-23, TNFα) and that this response is enhanced in macrophages from psoriasis patients. This effect is specific for IL-36γ and could not be mimicked by other IL-1 family cytokines such as IL-1α. Furthermore, IL-36γ stimulated macrophages potently activated endothelial cells as illustrated by ICAM-1(CD54) upregulation, and led to increased adherence of monocytes, effects that were markedly more pronounced for psoriatic macrophages. Interestingly, regardless of stimulus, monocytes isolated from psoriasis patients showed increased adherence to both the stimulated and unstimulated endothelium when compared to monocytes from healthy individuals. Collectively, these findings add to the growing evidence for IL-36γ having roles in psoriatic responses, by enhancing endothelium directed leukocyte infiltration into the skin and strengthening the IL-23/IL-17 pathway. Our findings also point to a cellular response which could potentially support cardiovascular comorbidities in psoriasis. / University of Bradford and the Centre for Skin Sciences

Psoriasis is a chronic inflammatory disease of the skin and joints. More recent data emphasize an association with dysregulated glucose and fatty acid metabolism, obesity, elevated blood pressure and cardiac disease, summarized as metabolic syndrome. TNF-a and IL-17, central players in the pathogenesis of psoriasis, are known to impair bone formation. Therefore, the relation between psoriasis and bone metabolism parameters was investigated. Two serum markers of either bone formation—N-terminal propeptide of type I procollagen (P1NP) or bone resorption—C-terminal telopeptide of type I collagen (CTX-I)—were analyzed in a cohort of patients with psoriasis vulgaris. In patients with psoriasis, P1NP serum levels were reduced compared to gender-, age-, and body mass index-matched healthy controls. CTX-I levels were indistinguishable between patients with psoriasis and controls. Consistently, induction of psoriasis-like skin inflammation in mice decreases bone volume and activity of osteoblasts. Moreover, efficient anti-psoriatic treatment improved psoriasis severity, but did not reverse decreased P1NP level suggesting that independent of efficient skin treatment psoriasis did affect bone metabolism and might favor the development of osteoporosis. Taken together, evidence is provided that bone metabolism might be affected by psoriatic inflammation, which may have consequences for future patient counseling and disease monitoring.

No description available.

No description available.

Chronic itch has a significant impact on quality of life for millions of patients worldwide, on a level comparable to that of chronic pain. Yet, although there are a host of effective drugs available for pain, there are no therapies that specifically target chronic itch. Current experimental approaches to investigate the pathogenesis of chronic pruritus and to test novel therapeutic agents are largely limited to rodent models. However, rodent models display significant dermatological, neurophysiological, and immunological differences from humans with chronic itch. The disadvantages of the current rodent paradigms call for the design of a valid primate model of chronic itch. For four years, we have monitored scratching behavior in a primate colony (n=35) of Cynomolgus macaques (Macaca fascicularis) suffering from idiopathic chronic itch. By comparing molecular and genetic analyses of the primates’ skin to their quantified scratching behavior, we attempted to characterize the underlying mechanisms of chronic itch in this model. Furthermore, the expression of itch-related proteins was examined in both the primate model and in humans with pruritic diseases. The first aim of the study was to characterize the underlying molecular and genetic basis of chronic itch in the primate model. We were able to distinguish specific peripheral targets related to pruritus by correlating the genetic and protein expression results to the primates’ scratching severity. In Aim 1a, RNA-sequencing was performed on skin biopsies from the primates to identify differentially expressed genes in pruritic, lichenified versus non-pruritic, non-lichenified skin. These results were then correlated to the quantified primate scratching behavior. This led to the identification of over 400 genes that were differentially expressed in the skin based on scratching intensity. Many of these differentially expressed transcripts were associated with sensory nerve fibers, keratinocytes, mast cells, or lymphocytes. Selected genes that were overexpressed and correlated to itch intensity were then targeted for immunohistochemical and proteomic analysis in Aim 1b. Immunohistochemical examination of the primate skin biopsies revealed that histamine levels were not elevated in primates that exhibited increased scratching behavior. However, mast cells containing tryptase were significantly increased in the skin of primates with severe scratching as compared to primates with mild scratching. The increased levels of gastrin-releasing peptide and substance P in lichenified skin were also found to be correlated to the primates’ scratching behavior. Of note, transient receptor potential channels V1, V3, and A1 were increased in the epidermis of primate skin, but the numbers of TRPV1+ and TRPA1+ nerve fibers were not significantly different between lichenified and non-lichenified skin. Transcriptome analysis of the opioid receptors and their ligands showed that primates with severe scratching behavior had a significant imbalance between the µ- and κ-opioid receptors and ligands. The µ-opioids had upregulated gene expression, while the κ-opioids were downregulated. In Aim 2, to further characterize this primate model of chronic itch, we compared immunohistochemical results from the primate studies to human findings. Lesional and non-lesional skin biopsies from patients with atopic dermatitis, psoriasis, and cutaneous T-cell lymphoma underwent immunohistochemical analysis in order to reveal the similarities and differences between the primate model and different types of chronic itch in humans. As in the primate model, substance P was found to be increased in the skin of lesional atopic and psoriasis skin. Additionally, similar to primate skin, human atopic and psoriatic skin had high levels of tryptase and its receptor in the epidermis. While IL-31 was only slightly elevated in primates, patients with cutaneous T-cell lymphoma or atopic dermatitis showed a significant correlation between itch severity and IL-31 levels. In conclusion, our primate model displayed expression patterns of many endogenous pruritogens and receptors that were similar to those of humans with atopic dermatitis or psoriasis. While the primate model did not completely mimic these specific pruritic diseases, the overlap of pruritic components suggests a commonality of signaling pathways across several different chronic itch states. The similarity of this primate model to human disease offers the combined advantages of experimental modeling and long-term behavioral follow-up. / Biomedical Sciences

No description available.

[ES] Nuestra investigación se centra en comprender los mecanismos moleculares que median las acciones de los glucocorticoides (GCs) en la fisiopatología de la piel mediante el análisis funcional del receptor de GCs (GR) y el receptor de mineralocorticoides (MR), dos proteínas altamente relacionadas estructural y funcionalmente, que actúan como factores de transcripción dependientes de ligando. Nuestros datos previos demuestran que GR juega un papel central en el desarrollo de la piel; en la edad adulta, tanto GR como MR actúan como mediadores anti-inflamatorios en enfermedades cutáneas (Sevilla et al. 2013; Boix et al. 2016). No obstante, desconocíamos si los receptores ejercían funciones cooperativas o antagónicas en la epidermis. Esta tesis doctoral se ha centrado en la generación y caracterización de ratones con inactivación específica en la epidermis de GR y MR (ratones double knock-out o DKO). Al nacer, los DKO mostraron un fenotipo cutáneo con diferenciación epidérmica defectuosa y un estado inflamatorio único caracterizado por infiltrados inmunes epiteliales y alteraciones en la expresión génica, similar a las lesiones psoriáticas. Este fenotipo fue mucho más severo que el de los KO individuales (ratones GR epidermal KO o GREKO y MR epidermal KO o MREKO), pero se resolvió espontáneamente a partir del día post-natal 3. En la edad adulta, la piel DKO mostró un aumento en el grosor epidérmico, similar al de los KO individuales. Todos los ratones KO mostraron una mayor susceptibilidad a la inflamación aguda respecto a los controles (CO), que no se contrarrestó de forma efectiva por un tratamiento tópico con GCs. Además, los ratones DKO mostraron una mayor susceptibilidad a la psoriasis inducida por imiquimod respecto a los KO individuales. El aumento de la respuesta inflamatoria en los DKO era consistente con un aumento significativo de la actividad de AP-1 y NF-kappaB en queratinocitos DKO respecto a los CO o KO individuales. En conjunto, nuestros datos demuestran que GR y MR epidérmicos actúan de manera cooperativa para contrarrestar la inflamación de la piel, durante el desarrollo y la edad adulta, y que ambos son necesarios para una respuesta transcripcional óptima y una actividad terapéutica de los GCs. Los tratamientos prolongados con dosis farmacológicas de GCs producen defectos como la atrofia cutánea, similar a la que tiene lugar durante el envejecimiento cronológico, que correlaciona con un aumento de los niveles locales endógenos de GCs. Este trabajo ha abordado las consecuencias fenotípicas de la pérdida epidérmica de MR durante el envejecimiento cronológico y los mecanismos involucrados. Los ratones MREKO de 13 meses de edad fueron resistentes a la atrofia epidérmica pero mostraron un menor grosor dérmico y depósito de colágeno, en parte debido a una disminución de la actividad SMAD2/3 respecto a la piel de ratones CO. Además, el tejido adiposo subcutáneo (dWAT) se engrosó 2.5 veces en MREKO vs CO a los 13 meses, con hiperplasia e hipertrofia de adipocitos. Estos cambios se desencadenaron, al menos en parte, a través de alteraciones en la señalización mediada por GCs, y la activación de WNT/beta-catenina inducida por señales paracrinas epidérmicas que condujeron al aumento de expresión de Pparg. Estos resultados demuestran un papel crucial de MR epidérmico en la regulación del cross-talk entre compartimientos durante el envejecimiento cronológico de la piel. / [CA] La nostra investigació se centra en comprendre els mecanismes moleculars que regulen les accions dels glucocorticoides (GCs) en la fisiopatologia de la pell mitjançant l'anàlisi funcional del receptor de GCs (GR) i el receptor de mineralocorticoides (MR), dues proteïnes altament relacionades estructural i funcionalment, que actuen com a factors de transcripció dependents de lligant. Els nostres resultats previs demostren que GR juga un paper central en el desenvolupament de la pell; en l'edat adulta, tant GR com MR actuen com a mediadors antiinflamatoris en malalties cutànies (Sevilla et al. 2013; Boix et al. 2016). No obstant, desconeixíem si els receptors exercien funcions cooperatives o antagòniques en l'epidermis. Aquesta tesi doctoral s'ha centrat en la generació i caracterització de ratolins amb inactivació específica en l'epidermis de GR i MR (ratolins double knock-out o DKO). En néixer, els DKO van mostrar un fenotip cutani amb diferenciació epidèrmica defectuosa i un estat inflamatori únic caracteritzat per infiltrats immunes epitelials i alteracions en l'expressió gènica, similar a les lesions psoriàtiques. Aquest fenotip va ser molt més sever que el dels KO individuals (ratolins GR epidermal KO o GREKO i MR epidermal KO o MREKO), però es va resoldre espontàniament a partir del dia post-natal 3. En l'edat adulta, la pell DKO va mostrar un augment en el gruix epidèrmic, similar al dels KO individuals. Tots els ratolins KO van mostrar una major susceptibilitat a la inflamació aguda en comparació als controls (CO), que no va ser contrarestada de manera efectiva per un tractament tòpic amb GCs. A més, els ratolins DKO van mostrar una major susceptibilitat a la psoriasis induïda per imiquimod respecte als KO individuals. L'augment de la resposta inflamatòria en els DKO era consistent amb un augment significatiu de l'activitat d'AP-1 i NF-kappaB en queratinòcits DKO respecte als CO o KO individuals. En conjunt, les nostres dades demostren que GR i MR epidèrmics actuen de manera cooperativa per contrarestar la inflamació de la pell, durant el desenvolupament i l'edat adulta, i que tots dos són necessaris per a una resposta transcripcional òptima i una activitat terapèutica dels GCs. Els tractaments prolongats amb dosis farmacològiques de GCs produeixen defectes com l'atròfia cutània, similar a la que té lloc durant l'envelliment cronològic, que correlaciona amb un augment dels nivells locals endògens de GCs. Aquest treball ha abordat les conseqüències fenotípiques de la pèrdua epidèrmica de MR durant l'envelliment cronològic i els mecanismes involucrats. Els ratolins MREKO de 13 mesos d'edat van ser resistents a l'atròfia epidèrmica però van mostrar un menor gruix dèrmic i dipòsit de col¿lagen, en part a causa d'una disminució de l'activitat SMAD2/3 respecte a la pell de ratolins CO. A més, el teixit adipós subcutani (dWAT) es va engrossir 2.5 vegades en MREKO vs CO als 13 mesos, amb hiperplàsia i hipertròfia d'adipòcits. Aquests canvis es van desencadenar, almenys en part, a través d'alteracions en la senyalització mediada per GCs, i l'activació de WNT/beta-catenina induïda per senyals paracrines epidèrmiques que van conduir a l'augment d'expressió de Pparg. Aquests resultats demostren un paper crucial de MR epidèrmic en la regulació del cross-talk entre compartiments durant l'envelliment cronològic de la pell. / [EN] Our research focuses on understanding the molecular mechanisms that mediate the actions of glucocorticoids (GCs) in skin pathophysiology through functional analysis of the GC receptor (GR) and the mineralocorticoid receptor (MR), two highly related structural and functionally proteins, which act as ligand-dependent transcription factors. Our previous data show that GR plays a central role in skin development; in adulthood, both GR and MR act as anti-inflammatory mediators in skin diseases (Sevilla et al. 2013; Boix et al. 2016). However, we did not know if the receptors exerted cooperative or antagonistic functions in the epidermis. This doctoral thesis has focused on the generation and characterization of mice with specific inactivation in the epidermis of GR and MR (double knock-out or DKO mice). At birth, DKO show a skin phenotype with defective epidermal differentiation and a unique inflammatory state characterized by epithelial immune infiltrates and alterations in gene expression, similar to psoriatic lesions. This phenotype was much more severe than that of individual KO (GR epidermal KO or GREKO and MR epidermal KO or MREKO mice), but resolved spontaneously from postnatal day 3. In adulthood, DKO skin showed an increase in epidermal thickness, similar to that of individual KO. All KO mice showed greater susceptibility to acute inflammation compared to controls (CO), which was not effectively counteracted by topical treatment with GCs. Furthermore, DKO mice show a greater susceptibility to imiquimod-induced psoriasis relative to individual KO. The increased inflammatory response in DKO was consistent with a significant increase in AP-1 and NF-kappaB activity in DKO keratinocytes relative to CO or individual KO. Taken together, our data show that epidermal GR and MR act cooperatively to counteract skin inflammation, during development and adulthood, and that both are required for optimal transcriptional response and therapeutic activity of GCs. Prolonged treatments with pharmacological doses of GCs produce defects such as cutaneous atrophy, similar to that which occurs during chronological aging, which correlates with an increase in endogenous local levels of GCs. This work has addressed the phenotypic consequences of epidermal loss of MR during chronological aging and the mechanisms involved. The 13-month-old MREKO mice were resistant to epidermal atrophy but displayed reduced dermal thickness and collagen deposition, in part due to a decrease in SMAD2 3 activity relative to the skin of CO mice. In addition, the subcutaneous adipose tissue (dWAT) thickened 2.5 times in MREKO vs CO at 13 months, with hyperplasia and hypertrophy of adipocytes. These changes were triggered, at least in part, through alterations in GC-mediated signaling, and the activation of WNT/beta-catenin induced by epidermal paracrine signals that led to increased expression of Pparg. These results show a crucial role for epidermal MR in the regulation of the cross-talk between compartments during chronological skin aging. / Este trabajo ha sido realizado con el apoyo económico de los proyectos de investigación que se enumeran a continuación: SAF2014-59474-R, SAF2017-88046-R. Judit Bigas Corominas ha disfrutado de una beca predoctoral FPI (BES2015-072722) otorgada por el Ministerio de Economía y Competitividad, asociada al proyecto SAF2014-59474-R. Agradecemos el apoyo de COST ADMIRE BM-1301 y NuRCaMeIn (SAF2015-71878-REDT y SAF2017-90604-REDT). / Bigas Corominas, J. (2020). Contribuciones relativas de los receptores de glucocorticoides y mineralocorticoides en la biología cutánea [Tesis doctoral]. Universitat Politècnica de València. https://doi.org/10.4995/Thesis/10251/156214